Transcription factors as targets for cancer therapy
The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
Abstract
A limited list of transcription factors are overactive in most human cancer cells, which makes them targets for the development of anticancer drugs. That they are the most direct and hopeful targets for treating cancer is proposed, and this is supported by the fact that there are many more human oncogenes in signalling pathways than there are oncogenic transcription factors. But how could specific transcription-factor activity be inhibited?
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“STAT3 is a member of a family of seven proteins known to play critical roles in cytokine and growth factor signaling (Darnell, 2002).”
From Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution (2020) · cites this paper as Darnell, 2002
Citations
Cites
1 retracted
Aoki, N., & Matsuda, T. (2002) · Molecular Endocrinology · doi:10.1210/mend.16.1.0761 · Cited by 119
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Notch Signaling: Cell Fate Control and Signal Integration in Development
Artavanis-Tsakonas, S., Rand, M. D., & Lake, R. J. (1999) · Science · doi:10.1126/science.284.5415.770 · Cited by 5,909
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I., Gascoyne, R. D., Muller-Hermelink, H. K., Smeland, E. B., Giltnane, J. M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012914 · Cited by 3,829
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
STATs: transcriptional control and biological impact
Levy, D. E., & Darnell, J. E. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm909 · Cited by 3,201
Dérijard, B., Hibi, M., Wu, I.-H., Barrett, T., Su, B., Deng, T., Karin, M., & Davis, R. J. (1994) · Cell · doi:10.1016/0092-8674(94)90380-8 · Cited by 3,188
Cited by
Items 301–400 of 1,001
Completion of a programmable DNA-binding small molecule library
Hsu, C. F., Phillips, J. W., Trauger, J. W., Farkas, M. E., Belitsky, J. M., Heckel, A., Olenyuk, B. Z., Puckett, J. W., Wang, C. C. C., & Dervan, P. B. (2007) · Tetrahedron · doi:10.1016/j.tet.2007.03.041 · Cited by 66
Altered expression of prolactin receptor-associated signaling proteins in human breast carcinoma
McHale, K., Tomaszewski, J., Puthiyaveettil, R., Livolsi, V., & Clevenger, C. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.7 · Cited by 75
“Signal transducers and activators of transcription (Stat) proteins encompass a family of five transcription factors (Stat1-5) that participate in several normal cellular events, such as differentiation, proliferation, cell survival, and apoptosis”
BackgroundTRIM 8 regulates stemness in glioblastoma through PIAS 3‐ STAT 3
Zhang, C., Mukherjee, S., Tucker‐Burden, C., Ross, J., Chau, M. J., Kong, J., & Brat, D. J. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12034 · Cited by 67
Sawyer, T. K. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.1.1 · Cited by 69
Pectasides, E., Egloff, A. M., Sasaki, C. T., Kountourakis, P., Burtness, B. A., Fountzilas, G., Dafni, U. G., Zaramboukas, T., Rampias, T. N., Rimm, D. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2658 · Cited by 69
Tran, K. Q., Tin, A. S., & Firestone, G. L. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000054 · Cited by 65
“The NF-κB p65/p50 heterodimer contains the transcriptional activation domain and is sequestered in the cytoplasm as an inactive complex by binding to IκB-α, an inhibitor of NF-κB [40, 41].”
BackgroundA Small Molecule That Binds and Inhibits the ETV1 Transcription Factor Oncoprotein
Pop, M. S., Stransky, N., Garvie, C. W., Theurillat, J.-P., Hartman, E. C., Lewis, T. A., Zhong, C., Culyba, E. K., Lin, F., Daniels, D. S., et al. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0689 · Cited by 65
“As an additional control to rule out nonspecific compound effects, we tested a small set of commercially available BRD32048 analogs that contain the [1,3,5]triazine core but vary either the methoxyphenyl group in the 4-position or the alkyl piperidine group in the 6-position.”
New strategies for immunosuppression: interfering with cytokines by targeting the Jak/Stat pathway
O’Shea, J. J., Park, H., Pesu, M., Borie, D. C., & Changelian, P. S. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000160781.07174.db · Cited by 63
Ivanov, V. N., & Hei, T. K. (2004) · Oncogene · doi:10.1038/sj.onc.1208125 · Cited by 71
Targeting MgrA-Mediated Virulence Regulation in Staphylococcus aureus
Sun, F., Zhou, L., Zhao, B.-C., Deng, X., Cho, H., Yi, C., Jian, X., Song, C., Luan, C.-H., Bae, T., et al. (2011) · Chemistry & Biology · doi:10.1016/j.chembiol.2011.05.014 · Cited by 67
Zhang, S., Metelev, V., TABATADZE, D. R., Zamecnik, P. C., & Bogdanov, A. A., Jr. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800162105 · Cited by 64
Oncogenic transcription factors: cornerstones of inflammation-linked pancreatic carcinogenesis
Baumgart, S., Ellenrieder, V., & Fernández-Zapico, M. E. (2011) · Gut · doi:10.1136/gutjnl-2011-301008 · Cited by 69
Kim, C., Baek, S. H., Um, J., Shim, B. S., & Ahn, K. S. (2016) · BMC Nephrology · doi:10.1186/s12882-016-0233-7 · Cited by 66
“Once STATs are activated, it translocates into the nucleus and controls the transcription of various oncogenic genes [3].”
BackgroundMyeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities
Kortylewski, M., & Moreira, D. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1966-2 · Cited by 67
Aguirre, J. D., Lutterman, D. A., Angeles-Boza, A. M., Dunbar, K. R., & Turró, C. (2007) · Inorganic Chemistry · doi:10.1021/ic700708g · Cited by 64
Molecular Pathways: Targeting ETS Gene Fusions in Cancer
Feng, F. Y.-C., Brenner, J. C., Hussain, M., & Chinnaiyan, A. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0275 · Cited by 76
Manavathi, B., Nair, S. S., Wang, R., Kumar, R., & Vadlamudi, R. K. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4664 · Cited by 64
“Signal transducers and activators of transcription (STAT) proteins are latent cytoplasmic transcription factors activated through receptors that bind cytokines, growth factors, or peptides ( 7 ).”
BackgroundInfluentialRUNX family: Oncogenes or tumor suppressors (Review)
Otálora-Otálora, B. A., Henr�quez, B., Kleine, L. L., & Rojas, A. P. (2019) · Oncology Reports · doi:10.3892/or.2019.7149 · Cited by 83
“Wnt binds to frizzled, thereby activating dishevelled, inhibiting glycogen synthase kinase 3β, and avoiding β‐catenin phosphorylation and destruction (7).”
BackgroundInfluentialAmphipathic Small Molecules Mimic the Binding Mode and Function of Endogenous Transcription Factors
Buhrlage, S. J., Bates, C. A., Rowe, S. P., Minter, A. R., Brennan, B. B., Majmudar, C. Y., Wemmer, D. E., Al‐Hashimi, H. M., & Mapp, A. K. (2009) · ACS Chemical Biology · doi:10.1021/cb900028j · Cited by 63
“Among these are CBP and the closely related p300,(15,16,49) several components of the Mediator complex (Med23, Med15, for example),(50-52) the SAGA chromatin-modifying complex (TRRAP (Tra1)), Taf12, and Sug2.”
BackgroundMethodInfluentialDhruv, H., Winslow, W. S. M., Armstrong, B. A., Tuncali, S., Eschbacher, J. M., Kislin, K. L., Loftus, J. C., Tran, N. L., & Berens, M. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072134 · Cited by 69
Anticancer Natural Compounds as Epigenetic Modulators of Gene Expression
Ratovitski, E. A. (2017) · Current Genomics · doi:10.2174/1389202917666160803165229 · Cited by 71
“TP53 family members, F-Box and WD repeat domain containing-7 protein FBXW7, Forkhead transcription factors, ETS transcription factor MEF [ELF4], RECK, SOX10) are transcription factors, as well [54-66].”
BackgroundRyu, K., Susa, M., Choy, E., Yang, C., Hornicek, F. J., Mankin, H. J., & Duan, Z. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-187 · Cited by 60
“Recently, Stat3 has been implicated as a promising target for cancer therapy [12,13,20,28-31].”
Xue, J., Shan, L., Chen, H., Li, Y., Zhu, H., Deng, D., Qian, Z., Achilefu, S., & Gu, Y. (2012) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2012.06.062 · Cited by 63
“Cancer is well known as a genetic disease (Bishop, 1987; Hahn and Weinberg, 2002), which is usually related to the abnormity of a number of signaling pathways that especially include some transcription factors (Cantley, 2002; Darnell, 2002; Hahn and Weinberg, 2002).”
BackgroundNanomolar Inhibitors of the Transcription Factor STAT5b with High Selectivity over STAT5a
Elumalai, N., Berg, A., Natarajan, K., Scharow, A., & Berg, T. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201410672 · Cited by 62
A novel activating function of c-Src and Stat3 on HGF transcription in mammary carcinoma cells
Wojcik, E. J., Sharifpoor, S., Miller, N., Wright, T. G., Watering, R., Tremblay, E. A., Swan, K., Mueller, C. R., & Elliott, B. E. (2005) · Oncogene · doi:10.1038/sj.onc.1209306 · Cited by 67
“The c-Src/Stat3-signalling pathway may therefore be an effective target (Darnell, 2002) for disruption of autocrine HGF loops in breast cancer and abrogation of metastasis.”
BackgroundLakhanpal, G. K., Vecchiarelli-Federico, L. M., Li, Y.-J., Cui, J.-W., Bailey, M. L., Spaner, D. E., Dumont, D. J., Barber, D. L., & Ben-David, Y. (2010) · Blood · doi:10.1182/blood-2009-10-250217 · Cited by 60
Gao, F., Chen, X., Wang, J., Chen, Y., Chao, H., & Ji, L. (2009) · Inorganic Chemistry · doi:10.1021/ic900902f · Cited by 60
Jiang, W., Mitra, R., Lin, C.-C., Wang, Q., Cheng, F., & Zhao, Z. (2015) · Briefings in Bioinformatics · doi:10.1093/bib/bbv107 · Cited by 66
Malek, A. V., Núñez, L. E., Magistri, M., Brambilla, L., Jovic, S., Carbone, G. M., Morís, F., & Catapano, C. V. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035130 · Cited by 66
“signaling pathways and the therapeutic benefits achievable by targeting individual pathways may be limited [1].”
Mandal, P. K., Limbrick, D., Coleman, D. R., Dyer, G. A., Ren, Z., Birtwistle, J. S., Xiong, C., Chen, X., Briggs, J. M., & McMurray, J. S. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm801491w · Cited by 59
Newly identified tumor-associated role of human Sharpin
Jung, J., Kim, J. M., Park, B., Cheon, Y., Lee, B., Choo, S. H., Koh, S. S., & Lee, S. (2010) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-010-0413-x · Cited by 59
“Many microarray-based studies have been undertaken with the idea that key tumor drug targets will be transcriptionally activated [7].”
BackgroundClinical, Pathological and Molecular Determinants in Squamous Cell Carcinoma of the Oral Cavity
Al-Swiahb, J. N., Chen, C., Chuang, H., Fang, F., Tasi, H.-T., & Chien, C. (2010) · Future Oncology · doi:10.2217/fon.10.35 · Cited by 59
“STAT proteins The STAT proteins include seven members (1, 2, 3, 4, 5A, 5B and 6), which are encoded by distinct genes in mammalian cells [81].”
BackgroundLee, K., Lee, D. E., Seo, S. K., Hwang, M. K., Heo, Y., Lee, H. J., & Lee, H. J. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq102 · Cited by 59
Soodgupta, D., Pan, D., Cui, G., Senpan, A., Yang, X., Lu, L., Weilbaecher, K. N., Prochownik, E. V., Lanza, G. M., & Tomasson, M. H. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0774-t · Cited by 59
Werden, S. J., Sphyris, N., Sarkar, T. R., Paranjape, A. N., LaBaff, A. M., Taube, J. H., Hollier, B. G., Ramirez‐Peña, E., Soundararajan, R., den Hollander, P., et al. (2016) · Oncogene · doi:10.1038/onc.2016.203 · Cited by 63
Arsenite Sensitizes Human Melanomas to Apoptosis via Tumor Necrosis Factor α-mediated Pathway
Ivanov, V. N., & Hei, T. K. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m314131200 · Cited by 61
DNA‐Binding Small Molecules as Inhibitors of Transcription Factors
Leung, C., Chan, D. S., Ma, V. P., & Ma, D. (2013) · Medicinal Research Reviews · doi:10.1002/med.21266 · Cited by 58
Li, B., Xia, A., Zhang, S., Suo, T., Ma, Y., Huang, H., Zhang, X., Chen, Y., & Zhou, X. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112619 · Cited by 58
DNA‐Templated Photonic Arrays and Assemblies: Design Principles and Future Opportunities
Su, W., Bonnard, V., & Burley, G. A. (2011) · Chemistry - A European Journal · doi:10.1002/chem.201100924 · Cited by 61
Saw, C. L. L., Wu, Q., & Kong, A. T. (2010) · Chinese Medicine · doi:10.1186/1749-8546-5-37 · Cited by 64
“Evidence supports the notion that blocking NF-kB is an important target for the control of inflammation and cancer [70,71].”
SAR by (Protein-Observed) 19F NMR
Divakaran, A., Kirberger, S. E., & Pomerantz, W. C. K. (2019) · Accounts of Chemical Research · doi:10.1021/acs.accounts.9b00377 · Cited by 60
Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer
Pradat, Y., Viot, J., Владимирович, Г. К., Yurchenko, A. A., Cerbone, L., Deloger, M., Grisay, G., Verlingue, L., Scott, V., Padioleau, I., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0966 · Cited by 64
Dubey, R., Levin, M. D., Szabó, L., László, C., Kushal, S., Singh, J. B., Oh, P., Schnitzer, J. E., & Olenyuk, B. Z. (2013) · Journal of the American Chemical Society · doi:10.1021/ja400805b · Cited by 64
Selective requirement for Mediator MED23 in Ras-active lung cancer
Xu, Y., Zhao, M. L., Xia, M. H., Liu, Y., Yan, J., Ji, H., & Wang, G. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1204311109 · Cited by 62
“Aberrant transcriptional regulation that results in malignant gene-expression patterns often accompanies carcinogenesis (39, 40).”
BackgroundKnockdown of β-catenin with Dicer-Substrate siRNAs Reduces Liver Tumor Burden In vivo
Dudek, H., Wong, D. H., Arvan, R., Shah, A., Wortham, K., Ying, B., Diwanji, R., Zhou, W., Holmes, B., Yang, H., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2013.233 · Cited by 57
Expression of the PTTG1 Oncogene Is Associated with Aggressive Clear Cell Renal Cell Carcinoma
Wondergem, B., Zhang, Z., Huang, D., Ong, C. K., Koeman, J. M., Hof, D. V., Petillo, D., Ooi, A., ANEMA, J. G., Lane, B. R., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2330 · Cited by 64
Tseng, Y., & Bagchi, A. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.974467 · Cited by 57
“However, so far it has not been possible to target MYC directly.(9) JQ1, a small molecule inhibitor of bromodomain 4 (Brd4) has recently been shown to indirectly inhibit MYC transcription in hematological malignancies.”
BackgroundA novel target for treatment of chordoma: signal transducers and activators of transcription 3
Yang, C., Schwab, J. H., Schoenfeld, A. J., Hornicek, F. J., Wood, K. B., Nielsen, G. P., Choy, E., Mankin, H., & Duan, Z. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0504 · Cited by 57
Essential role of O-GlcNAcylation in stabilization of oncogenic factors
Makwana, V., Ryan, P., Patel, B., Anoopkumar‐Dukie, S., & Rudrawar, S. (2019) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2019.04.002 · Cited by 62
Chen, J., Nikolovska‐Coleska, Z., Yang, C., Gomez, C., Gao, W., Krajewski, K., Jiang, S., Roller, P. P., & Wang, S. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2007.04.096 · Cited by 59
TRPV1 Channels in Immune Cells and Hematological Malignancies
Omari, S. A., Adams, M. J., & GERAGHTY, D. P. (2017) · Advances in pharmacology · doi:10.1016/bs.apha.2017.01.002 · Cited by 63
Amani, H., Ajami, M., Maleki, S. N., Pazoki–Toroudi, H., Daglia, M., Sokeng, A. J. T., Lorenzo, A. D., Nabavi, S. F., Devi, K. P., & Nabavi, S. M. (2017) · Biochimie · doi:10.1016/j.biochi.2017.08.007 · Cited by 56
Opportunities for Therapeutic Modulation of O-GlcNAc
Cheng, S. S., Mody, A. C., & Woo, C. M. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.4c00417 · Cited by 67
Identification of a Polyoxometalate Inhibitor of the DNA Binding Activity of Sox2
Narasimhan, K., Pillay, S., Ahmad, N. R. B., Bikádi, Z., Hazai, E., Yan, L., Kolatkar, P. R., Pervushin, K. V., & Jauch, R. (2011) · ACS Chemical Biology · doi:10.1021/cb100432x · Cited by 65
Yousuf, S., Duan, M., Moen, E. L., Cross-Knorr, S., Brilliant, K. E., Bonavida, B., LaValle, T., Yeung, K. C., Al‐Mulla, F., Chin, E. Y., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092478 · Cited by 59
“and lysine residues in the carboxy-terminal region [3–6].”
BackgroundRetractedFOXM1 and its oncogenic signaling in pancreatic cancer pathogenesis
Huang, C., Du, J., & Xie, K. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.01.002 · Cited by 64
“Therefore, recent research efforts have focused on this activation mechanism and targeting of the activity of transcription factors, which ultimately control the expression of genes involved in almost all aspects of pancreatic cancer cell biology [25,26].”
Kavandi, L., Collier, M. A., Nguyen, H., & Syed, V. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24191 · Cited by 61
Luker, K. E., & Piwnica-Worms, D. R. (2004) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/s0076-6879(04)85019-5 · Cited by 57
Targeting Transcription Factor YY1 for Cancer Treatment: Current Strategies and Future Directions
Hosea, R., Hillary, S., Wu, S., & Kasim, V. (2023) · Cancers · doi:10.3390/cancers15133506 · Cited by 58
Lee, A. W.-M., & States, D. J. (2006) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401884 · Cited by 59
“Full transcriptional activity of Stat3 requires phosphorylation at Tyr 705 and Ser 727.(23) Stat3C was dually phosphorylated in DKI/ Stat3C cells (Supplemental Figure S3b), but Stat3C had only Figure 2 PI3-kinase, and less so, Erk, but not Stat3, are critical for CSF-1-mediated mitogenesis.”
BackgroundSengupta, S., Biarnes, M. C., & Jordan, V. C. (2013) · Breast Cancer Research and Treatment · doi:10.1007/s10549-013-2789-2 · Cited by 58
“Although targeting cMYC represents an obvious therapeutic opportunity to block the growth of the resistant breast cancer cells, this has not been successful due to the lack of a drug-able domain in its ‘basic helix-loop-helix’ structure [14].”
BackgroundMagaye, R., Zhou, Q., Bowman, L. L., Zou, B., Mao, G., Xu, J., Castranova, V., Zhao, J., & Ding, M. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092418 · Cited by 55
“Activated AP-1 and NF-kB are found in many different cancer cells [33] and may result in the expression of target genes that are involved in neoplastic transformation and tumor progression [34].”
BackgroundStructure and decoy-mediated inhibition of the SOX18/Prox1-DNA interaction
Klaus, M., Prokoph, N., Girbig, M., Wang, X., Huang, Y., Srivastava, Y., Hou, L., Narasimhan, K., Kolatkar, P. R., François, M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw130 · Cited by 56
“As the DNA binding domains of TF proteins are widely deemed ‘undruggable’ using small-molecules (20,21), alternative strategies need to be considered to make this target class accessible for cancer therapy (22).”
Modulation of oncogenic transcription factors by bioactive natural products in breast cancer
Hasanpourghadi, M., Pandurangan, A. K., & Mustafa, M. R. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.009 · Cited by 59
“STATs Signal Transducers and Activators of Transcriptions (STATs) are ytoplasm resident group of transcription factors.”
BackgroundInfluentialMialon, A., Sankinen, M., Söderström, H., Junttila, T. T., Holmström, T., Koivusalo, R., Papageorgiou, A. C., Johnson, R. S., Hietanen, S., Elenius, K., et al. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.12.5040-5051.2005 · Cited by 55
“Recent studies have indicated that the regulation of expression of growth factors and their cell surface receptors is an important mechanism by which intracellular signaling pathways regulate cell proliferation (6, 7, 24).”
BackgroundTranscription Repressor Activity of Spleen Tyrosine Kinase Mediates Breast Tumor Suppression
Wang, L., Devarajan, E., He, J., Reddy, S. P., & Dai, J. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2231 · Cited by 55
“The full-length Syk(L) was carboxylterminally fused in frame to the Gal4 DNA-binding domain (1-147) that is expressed under the control of a CMV promoter (pFA-CMV).”
STAT3 transcription factor as target for anti-cancer therapy
Mohassab, A. M., Hassan, H. A., Abdelhamid, D. S., & Abdel‐Aziz, M. (2020) · Pharmacological Reports · doi:10.1007/s43440-020-00156-5 · Cited by 59
STAT3 Regulates Lytic Activation of Kaposi's Sarcoma-Associated Herpesvirus
King, C. A., Li, X., Barbachano-Guerrero, A., & Bhaduri‐McIntosh, S. (2015) · Journal of Virology · doi:10.1128/jvi.02008-15 · Cited by 54
“Dysregulation of STAT3 is linked to most human cancers, including KSHV PEL and KS (23, 41, 42).”
BackgroundDNA mimicry by a high-affinity anti-NF-κB RNA aptamer
Reiter, N. J., Maher, L. J., & Butcher, S. E. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm1141 · Cited by 56
“Because of its role in activating genes involved in inflammation, inhibition of apoptosis and HIV-1 activation, this dimeric transcription factor is of interest as a potential target for therapeutic inhibition (5,6).”
BackgroundPandey, V., Chaube, B., & Bhat, M. K. (2011) · Journal of Cellular Biochemistry · doi:10.1002/jcb.23210 · Cited by 54
“In addition, it has been previously shown that persistent nuclear localization and constitutive activation of NF-kB is important for survival and oncogenesis in tumors of breast, ovarian, colon, thyroid, prostate, and melanoma [Rayet and Gelinas, 1999; Darnell, 2002].”
BackgroundLevings, D. C., Wang, X., Kohlhase, D., Bell, D. A., & Slattery, M. G. (2018) · Redox Biology · doi:10.1016/j.redox.2018.07.026 · Cited by 55
Mol, E. D., Szulc, E., Sanza, C. D., Martínez-Cristóbal, P., Bertoncini, C. W., Fenwick, R. B., Frigolé‐Vivas, M., Masin, M., Hunter, I., Buzón, V., et al. (2017) · Structure · doi:10.1016/j.str.2017.11.007 · Cited by 58
“It is important to characterize these interactions because their inhibition by small molecules or other biological tools offers opportunities for therapeutic intervention in many disease areas, including oncology (Darnell, 2002).”
Liang, Y., Zhang, T., Jing, S., Zuo, P., Li, T., Wang, Y., Xing, S., Zhang, J., & Wei, Z. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x2150035x · Cited by 57
Functions and mechanisms of protein disulfide isomerase family in cancer emergence
Rahman, N. S. A., Zahari, S., Syafruddin, S. E., Firdaus‐Raih, M., Low, T. Y., & Mohtar, M. A. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00868-6 · Cited by 61
“Moreover, in patients with melanoma or refractory acute myeloid leukemia, PDIA1 is an immunogenic molecule that is targeted by antibodies during immunemediated tumor breakdown [133, 134].”
BackgroundPeng, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1326 · Cited by 59
“Constitutive activation of STAT3 is one of the major oncogenic pathways involved in the development of CRC and thus becomes a promising therapeutic target (23-28).”
BackgroundHill, E. R., Koganti, S. R. K., Zhi, J., Megyola, C. M., Freeman, A. F., Palendira, U., Tangye, S. G., Farrell, P. J., & Bhaduri‐McIntosh, S. (2013) · Journal of Virology · doi:10.1128/jvi.01762-13 · Cited by 53
“STAT3 drives prosurvival and proproliferative functions (12, 13) and is overactive in most human cancers (14).”
BackgroundDNA minor groove binding of small molecules: Experimental and computational evidence
Pandya, P., Islam, M. M., Kumar, G. S., Jayaram, B., & Kumar, S. (2010) · Journal of Chemical Sciences · doi:10.1007/s12039-010-0029-4 · Cited by 53
Signal Transducers and Activators of Transcription as Targets for Small Organic Molecules
Berg, T. (2008) · ChemBioChem · doi:10.1002/cbic.200800274 · Cited by 53
Fan-Minogue, H., Bodapati, S., Solow-Cordero, D. E., Fan, A. C., Paulmurugan, R., Massoud, T. F., Felsher, D. W., & Gambhir, S. S. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1243 · Cited by 53
“Since c-Myc lacks a clear ligand-binding domain for direct interaction (40), NTZ most likely affects c-Myc activity indirectly, and possibly via multiple routes.”
BackgroundVázquez, O., Vázquez, M. E., Blanco‐Canosa, J. B., Castedo, L., & Mascarenas, J. L. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200702345 · Cited by 53
Transcription factors, chromatin and cancer
Thorne, J. L., Campbell, M. J., & Turner, B. M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.029 · Cited by 61
Venkatasubbarao, K., Choudary, A., & Freeman, J. W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2396 · Cited by 51
“Surmounting evidence indicate that targeting STAT3 is of therapeutic importance ( 72 , 73).”
FLI1 promotes IFN-γ-induced kynurenine production to impair anti-tumor immunity
Chen, E., Wu, J., Huang, J., Zhu, W., Sun, H., Wang, X., Lin, D., Li, X., Shi, D., Liu, Z.-Q., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-48397-9 · Cited by 63
Programmable Oligomers for Minor Groove DNA Recognition
Doss, R. M., Marques, M. A., Foister, S., Chenoweth, D. M., & Dervan, P. B. (2006) · Journal of the American Chemical Society · doi:10.1021/ja0621795 · Cited by 52
Huang, C., Lu, S.-H., Chang, C.-C., Thomas, P. A., Jayakumar, T., & Sheu, J. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.11.011 · Cited by 56
Truncation, Randomization, and Selection
Crooks, R. O., Rao, T., & Mason, J. M. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.221267 · Cited by 58
Small-Molecule Inhibitors of the SOX18 Transcription Factor
Fontaine, F. R., Overman, J. P., Moustaqil, M. D., Mamidyala, S. K., Salim, A. A., Narasimhan, K., Prokoph, N., Robertson, A. A. B., Lua, L. H. L., Alexandrov, K. A., et al. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.01.003 · Cited by 52
Inhibition of survival signalling by dietary polyphenols and indole-3-carbinol
Manson, M. M. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.05.008 · Cited by 53
“This pathway is central to the inflammatory response, but is also intimately involved in many cancers [8] and has been considered as a suitable target for cancer therapy [9].”
BackgroundDuring Human Melanoma Progression AP‐1 Binding Pairs are Altered with Loss of c‐Jun In Vitro
Yang, S., McNulty, S. E., & Meyskens, F. L. (2004) · Pigment Cell Research · doi:10.1046/j.1600-0749.2003.00114.x · Cited by 51
Transcription factor proteomics—Tools, applications, and challenges
Simicevic, J., & Deplancke, B. (2016) · PROTEOMICS · doi:10.1002/pmic.201600317 · Cited by 62
Signal Transducer and Activator of Transcription 3 - A Promising Target in Colitis-Associated Cancer
Pandurangan, A. K., & Esa, N. M. (2014) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2014.15.2.551 · Cited by 53
“Frequent mutations of the β-catenin gene were found in chemically induced colon tumors in both rat and mouse carcinogenesis models (Takahashi et al., 1998; Dashwood et al., 1998; Suzui et al., 1999).”
Competition dialysis: A method for the study of structural selective nucleic acid binding
Ragazzon, P. A., Garbett, N. C., & Chaires, J. B. (2007) · Methods · doi:10.1016/j.ymeth.2006.09.010 · Cited by 51
Li, W., Yan, Q., Ding, X., Shen, C., Hu, M., Zhu, Y., Qin, D., Lu, H., Krueger, B. J., Renne, R., et al. (2016) · PLoS Pathogens · doi:10.1371/journal.ppat.1005605 · Cited by 58
Global transcriptional analysis identifies a novel role for SOX4 in tumor-induced angiogenesis
Vervoort, S. J., de Jong, O. G., Roukens, M. G., Frederiks, C. L., Vermeulen, J. F., Lourenço, A. R., Bella, L., Vidaković, A. T., Sandoval, J. L., Moelans, C. B., et al. (2018) · eLife · doi:10.7554/elife.27706 · Cited by 52
In Silico Simulation of Inhibitor Drug Effects on Nuclear Factor-κB Pathway Dynamics
Sung, M., & Simon, R. M. (2004) · Molecular Pharmacology · doi:10.1124/mol.66.1.70 · Cited by 49
Zhu, H., Wang, J., Zhang, Q., Pan, X., & Zhang, J. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108371 · Cited by 56
WANG, X., ZHANG, Y., ZHANG, X., TIAN, W., FENG, W., & CHEN, T. (2012) · International Journal of Oncology · doi:10.3892/ijo.2011.1298 · Cited by 48
“Stat3 drives malignant progression through the deregulation of key proteins, including cell survival proteins such as Bcl-XL, Bcl-2, Mcl-1 and survivin (10,22-26), cell growth proteins such as cyclin D1/D2 and c-myc (9,27-31), inducers of angiogenesis such as vascular endothelial growth factor (VEGF)”
BackgroundE2F4 regulatory program predicts patient survival prognosis in breast cancer
Khaleel, S. S., Andrews, E. H., Ung, M. H., DiRenzo, J., & Cheng, C. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0486-7 · Cited by 49
“Unsurprisingly, aberrant expression or mutation of TFs or of their upstream signaling proteins has been implicated in an array of human diseases, including cancer [18-20].”
BackgroundMolecular cloning and functional analysis of a novel oncogene, cancer-upregulated gene 2 (CUG2)
Lee, S., Gang, J., Jeon, S. B., Choo, S. H., Lee, B., Kim, Y.-G., Lee, Y. S., Jung, J., Song, S. Y., & Koh, S. S. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.06.102 · Cited by 48
Wen, J., Feng, Y., Huang, W., Chen, H., Liao, B., Rice, L., Preti, H. A., Kamble, R. T., Zu, Y., Ballon, D., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.05.024 · Cited by 49
Metadata
- Authors
- Darnell, J. E.
- Venue
- Nature Reviews Cancer
- Published
- 2002-10
- Volume
- 2
- Issue
- 10
- Pages
- 740-749
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W1980480652
- Cited by
- 1,194
- References
- 109
- Citations by year
- 2026: 29 · 2025: 37 · 2024: 41 · 2023: 48 · 2022: 37 · 2021: 45 · 2020: 48 · 2019: 48 · 2018: 47 · 2017: 64 · 2016: 50 · 2015: 77 · 2014: 76 · 2013: 87 · 2012: 73
- FWCI
- 3.93
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- transcription factors, cancer therapy, anticancer drug targets, oncogenes, oncogenic transcription factor, signaling pathways, transcription factor inhibition
- MeSH terms
- Antineoplastic Agents, Cytoplasm, Cytoskeletal Proteins, Humans, Ligands, Models, Biological, Mutation, Neoplasms, Protein Binding, Proto-Oncogene Proteins, Transcription Factors, Transcription, Genetic, Signal Transduction, Trans-Activators, NF-kappa B, Apoptosis, Zebrafish Proteins, Wnt Proteins, beta Catenin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.